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26 
Abstract 27 
Purpose: To investigate effect of topical anaesthetic (TA) during gas permeable (GP) contact lens (CL) fitting 28 
on subjective and objective measures of patient anxiety. 29 
 30 
Methods: 47 subjects (mean±sd age = 26.9±4.9 years; soft CL wearers, 18, neophytes, 29). Each subject 31 
randomly assigned to Group A or B, and attended on two occasions, one week apart. First visit: subject 32 
received bilaterally either a single drop of TA (0.5% proxymetacaine) (Group A) or placebo (0.9% saline) 33 
(Group B) prior to GP CL application. No drops were instilled at second visit. Each visit mimicked a GP CL 34 
fitting. At each visit, patient anxiety was assessed either subjectively (visual analogue scale (VAS)) or 35 
objectively (skin conductance (SC)), as well as anterior ocular health. 36 
 37 
Results: Visit 1: GP CL trial produced small increases in hyperaemia and corneal staining, but no difference 38 
associated with TA use. Visit 2: increases in staining and hyperaemia were observed, but hyperaemic 39 
responses significantly less than at Visit 1, for both groups. Corneal staining also less, but not statistically 40 
significant. VAS scores indicated subjects who received TA during Visit 1 were significantly less anxious at 41 
Visit 2. Visit 2: comfort slightly reduced for subjects who received TA at Visit 1, and significantly increased for 42 
subjects who received placebo. Use of TA reduced anxiety during lens adaptation period compared with 43 
subjects receiving placebo. 44 
 45 
Conclusions: TA use during GP CL fitting has potential patient benefits: improved first-time GP CL wear 46 
comfort, reduced anxiety during adaptation, reduced anxiety prior to subsequent GP CL wear. 47 
 48 
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 50 
Highlights 51 
Use of topical anaesthetic during gas permeable (GP) contact lens (CL) fitting is clinically safe, improves first-52 
time GP CL wear comfort, reduces anxiety during adaptation and in subsequent CL wear. 53 
 54 
55 
The decline in rigid gas permeable (GP) contact lens (CL) prescribing is well documented1. In a previous 56 
study, we showed that the initial wearing discomfort with GP CLs discourages practitioners from 57 
recommending this lens type to patients2. Topical anaesthetic (TA) use in rigid gas permeable fitting results 58 
in enhanced initial patient comfort3, and may also reduce patient anxiety about initial lens comfort3. If initial 59 
comfort is improved with TA, particularly in patients perceived to have high ocular touch sensitivity or are 60 
anxious, practitioners may feel encouraged to consider GP CLs as a potential option4. However, the use of 61 
topical anaesthetic to aid GP CL fitting, is not common practice in the United Kingdom and practitioner 62 
opinion is divided on the acceptability of TA during GP CL fitting without evidence on the safety and benefit 63 
of TA use. 64 
 65 
Anxiety is the adaptive response to a threat, for example, in response to a clinical procedure5. Anxiety is 66 
known to influence patient success with CL6.7. It has been suggested that patients may not try CL because 67 
they are anxious about having them placed on their eyes7. Anxiety levels appear to vary between individuals 68 
and both internal and external forces may influence anxiety levels. Spielberger8 suggested that ‘trait’ anxiety 69 
refers to a person prone to anxiety, i.e. it is a fixed personality trait, while ‘state’ anxiety is a transient 70 
anxiety experience8. 71 
 72 
Use of TA makes the first GP CL experience more comfortable, but this raises questions over whether this 73 
makes the next visit, without TA, a worse experience, and therefore misleads a patient. Literature shows 74 
that use of TA results in less patient dropouts following the fitting phase3, however an insight into patient 75 
experience over the fitting phase would be advantageous. 76 
 77 
This study investigated the effects of TA use, during GP CL fitting, on the ocular surface to assess its safety of 78 
use; on subjective and objective measures of patient anxiety; and of previous TA use on the second patient 79 
experience with GP CL. 80 
 81 
Methods 82 
A prospective, randomised, double-masked cohort study was conducted involving two visits, scheduled with 83 
one week between visits. 84 
 85 
Subjects 86 
Forty-seven healthy, volunteer, subjects from staff and students within Cardiff University completed the 87 
study, m 20, f 27, mean±sd age = 26.9±4.9 years (range 18-45). Twenty-nine subjects were neophyte and 18 88 
had experience of or were current soft CL wearers. Subjects were excluded if they had worn GP CL before, 89 
suffered from any ocular condition including dry eye or any systemic condition known to affect the tear film 90 
or cornea, were taking any medication known to affect the tear film or cornea, or were pregnant or breast-91 
feeding. Ethical permission for the study was obtained from the School of Optometry and Vision Sciences 92 
Ethical Committee and signed informed consent was obtained from all subjects. All procedures conformed to 93 
the tenets of the Declaration of the Helsinki. 94 
 95 
Study Groups 96 
Subjects were randomly assigned to two groups (A or B) and either received a single drop of TA (A) or saline 97 
placebo (B) prior to GP CL application at the first visit, in both eyes, respectively. Group A (n=25) had a 98 
mean±sd age of 27.1±4.6 years, m 11, f 14. Group B (n=22) had a mean±sd age of 26.6±5.2 years, m 9, f 13. 99 
 100 
State and trait anxiety questionnaire 101 
The Spielberger State-Trait Inventory (STAI)9 incorporates two 20-item question sets measuring state and 102 
trait anxiety. The items are generic and the STAI has been used to measure anxiety in many healthcare 103 
studies10,11,12. The full STAI is lengthy and has been shortened to two 6-item scales9,13,14. Each item has four 104 
possible responses, with each response giving a score, and the anxiety result is found by summing the 105 
response scores. The shortened State-Trait scales were completed by all subjects prior to drop instillation 106 
and GP insertion. 107 
 108 
Visual analogue scale 109 
An anxiety visual analogue scale (VAS) was completed prior to GP CL application to indicate subject 110 
anxiety15,16, 17. Subjects were asked to mark their answer on the VAS to the question “How anxious do you 111 
feel about having contact lenses on your eyes today?”, between the two extremes of “Not at all anxious’ and 112 
‘Very anxious’. A comfort VAS was completed after GP fitting to indicate how comfortable the lenses had 113 
been on the eyes in response to the question “How did the contact lenses feel on your eyes today?”, 114 
between the two extremes of ‘Not at all comfortable’ and ‘Very comfortable’. 115 
 116 
Skin conductance recording procedure 117 
Skin conductance (SC) shows the emotional state reflected by changes in the sympathetic nervous system as 118 
a result of stress or arousal. Sympathetic activation causes release of acetylcholine, which acts on the 119 
muscarinic receptors leading to sweat production and a skin conductance increase18. SC has been used as a 120 
tool for monitoring post-operative pain in medicine19. It has been found to be better than alternative 121 
objective methods, e.g. heart rate, blood pressure and electroencephalograph (EEG), at detecting pain18. 122 
 123 
Skin conductance was measured by attaching 2 silver-silver chloride electrodes (coated with electrode gel) to 124 
the pads of the index and middle finger of the subject’s left hand. Signals from the electrodes were amplified 125 
(x2000) and low pass filtered (0-35Hz) using a physiological amplifier (Biopac MP30) connected to a laptop 126 
PC (Toshiba Satellite Pro 4200) running Biopac Student Lab Pro software (version 3.65, BIOPAC Systems Inc, 127 
Goleta, CA). All subjects washed their hands with a liquid soap prior to having the electrodes attached to 128 
improve the quality of contact. A period of 10 minutes was allowed to elapse before data collection to 129 
ensure the skin had fully absorbed the gel. The subject was asked to keep their hand still, resting on their left 130 
leg throughout the consultation. Conversation during the consultation was controlled and the same 131 
explanations and reassurance were given to all participants. 132 
 133 
SC response occurs with a latency of 1-3 seconds following a stimulus, making it difficult to directly link a 134 
response to a particular event23. For this reason, tags were helpful in marking periods of interest. Specific 135 
phrases were used by the examiner at key points during the consultation, and simultaneously the examiner 136 
added a tag to the trace (Figure 1). Tags were also added to the SC trace to identify completion of a 137 
particular task during the consultation. When subjects returned for the second visit, Tag 1 was omitted and 138 
only Tags 2-5 were inserted onto the SC trace. 139 
 140 
Tag 1 Examiner says, “I’m going to put a drop into your eyes now” 141 
Tag 2 Examiner says, “I’m now going to insert the lenses to your eyes” 142 
Tag 3 Completion of lens insertion 143 
Tag 4 Examiner says, “I’m now going to remove the lenses from your eyes” 144 
Tag 5 Completion of lens removal 145 
 146 
Using the tags, information from the trace, such as mean response and maximal response, were determined 147 
within these periods of interest. Maximal response was selected as the key result for analysis in the results 148 
because this gave the subject’s peak arousal or anxiety experienced within each period. Absolute SC values 149 
do not facilitate comparison of SC between individuals. Therefore, SC values recorded during the ‘run-in 150 
period’ (from the start of the trace until drop insertion) were averaged and subtracted from subsequent 151 
recordings to normalise the data in all subjects. 152 
 153 
Anterior eye assessment 154 
At both visits, the health of the anterior eye was assessed using a slit-lamp. White light assessment allowed 155 
grading of conjunctival and limbal hyperaemia, according to the CCLRU grading scale. A sodium fluorescein 156 
sterile ophthalmic strip (FS) (Chauvin Pharmaceuticals, Romford, UK) was wetted with non-preserved 0.9% 157 
saline (Oxysept Saline; Abbott Medical Optics, High Wycombe, UK) and the FS applied to the inferior tarsal 158 
conjunctiva. Tear film fluorescence was enhanced with cobalt blue light, in conjunction with a Wratten Filter 159 
(No 12) in front of the objective lens. The corneal integrity was assessed and any corneal staining was 160 
recorded diagrammatically, and also graded using the CCLRU grading scale. 161 
 162 
At the first visit only, corneal keratometry of both eyes was measured using a 2-position Javal-Schiötz type 163 
keratometer (Topcon Corporation, Tokyo, Japan). 164 
 165 
Schedule 166 
Subjects were invited to attend for two GP CL fitting sessions, with a one-week separation between the two 167 
visits. The first visit mimicked a first GP CL fitting session when either TA or placebo drops were instilled. The 168 
second visit mimicked a second GP CL fitting session and no drops were instilled. 169 
 170 
Based on the keratometry measurement, an appropriate GP CL was selected from a fitting set (Quasar, No7 171 
Contact Lenses, Hastings, UK). All lenses had a total diameter of 9.60mm and back vertex power of -3.00 172 
Dioptres. The required lenses were cleaned and rinsed using Boston Advance 2-step system (Bausch & 173 
Lomb, Kingston-upon-Thames, UK). To mimick a CL fitting session, the selected CLs were then applied to 174 
both eyes while the patient’s eyes were in down-gaze. Once the lenses were settled and tearing had 175 
reduced or stopped, the lens fit was assessed. The examiner advised the subject that lenses were to be 176 
removed, which was then done by placing mild pressure on the inferior and superior lid margins, and 177 
digitally moving the lids together to release the lens. Conjunctival hyperaemia and limbal injection were re-178 
graded and corneal staining was noted and graded. Further FS was instilled at this stage only if required, 179 
since successive FS instillation is known to increase corneal staining20. 180 
 181 
Group A volunteers received 1 drop of 0.5% proxymetacaine hydrochloride (proparacaine) (Chauvin 182 
Pharmaceuticals, Romford, UK) in both eyes. Group B received 1 drop of 0.9% saline (Chauvin 183 
Pharmaceuticals, Romford, UK) in both eyes. Coloured tape was used to code the minims to mask both 184 
subject and examiner to the drops being administered. 185 
 186 
On each visit, patient anterior ocular health, and subjective and objective patient anxiety were measured. 187 
Keratometry was undertaken at the first visit only (Keratron Scout topographer (KS-1000), Optikon, Rome, 188 
Italy). 189 
 190 
Statistical analysis 191 
Data was analysed using SPSS 16.0 (SPSS Inc., Chicago, USA) and examined for normality by the Shapiro-Wilk 192 
test and appropriate statistical tests used. A probability value of <0.05 was used for statistical significance. 193 
Differences between groups were assessed by unpaired t-test (parametric) or U-Test Mann-Whitney (non-194 
parametric data). Internal reliability of the short version state and trait questionnaires was assessed using 195 
Cronbach alpha. Post-hoc Wilks’ Lambda was used to assess within-group interactions. Interpolation of the 196 
CCLRU grading scale produces an approximate interval scale and it has been argued that parametrical 197 
statistical tests may be applied to such data20, consequently parametric tests have been used predominantly 198 
Statistically, no significant difference was found between the eyes and therefore right eye data is presented 199 
throughout. 200 
 201 
Results 202 
Physiological effects 203 
At Visit 1, no significant difference was found in baseline ocular surface grading between the two groups 204 
(Table 1). Following GP CL application, conjunctival and limbal hyperaemia, and corneal staining was 205 
significantly increased in both groups when compared to their baseline measures (Figure 2). Comparison of 206 
grading pre- and post-GP fitting revealed no significant differences between the groups for hyperaemia or 207 
corneal staining change. Likewise, comparison of final CCLRU scores revealed no statistical difference 208 
between the groups. 209 
 210 
At Visit 2, no significant difference was found in baseline grades for limbal and conjunctival hyperaemia or 211 
corneal staining between the groups. Following GP CL application, both groups showed an increase in mean 212 
hyperaemia and corneal staining scores (Table 1) (Figure 3). There was a significant increase in hyperaemia 213 
and corneal grading scores between the pre- and post-GP CL fitting for Group A. The hyperaemia increase in 214 
Group B was not statistically significant when comparing before and after GP grading. Comparison of 215 
difference in grade (pre- and post-GP) between groups revealed no significant difference in hyperaemic 216 
response between the groups. Following GP CL fitting, corneal staining was significantly increased in both 217 
groups, however there was a significantly greater corneal response in Group A compared with Group B 218 
(Figure 4). 219 
Psychological effects 220 
Internal reliability of the short version state and trait questionnaires was assessed using Cronbach alpha. 221 
Cronbach alpha values for state anxiety analysis were: Visit 1, α=0.97; Visit 2, α=0.99, indicating a high 222 
degree of consistency, and making comparison of state anxiety results statistically reliable22. 223 
 224 
Inter-group trait scores were similar at Visit 1 and 2 for Group A (p=0.97, Mann-Whitney) and Group B 225 
(p=0.63, Mann-Whitney). State anxiety showed no significant difference between groups in baseline anxiety 226 
at Visit 1 (p=0.56, Mann-Whitney). No significant change in state anxiety was evident between Visit 1 and 2 227 
for Group A (p=0.35, Mann-Whitney), but Group B had increased state anxiety at Visit 2 (p<0.05, Mann-228 
Whitney) (Figure 5). 229 
 230 
There was no significant difference between Group A and B VAS anxiety scores at Visit 1. At Visit 2, Group A 231 
were significantly less anxious about lens application. Group B were marginally more anxious at Visit 2, 232 
though this finding was not statistically significant. Comparison of the change in anxiety over the two visits, 233 
between groups, was not significant (Table 2) (Figure 6). 234 
 235 
At Visit 1, initial GP VAS comfort scores were higher in Group A compared with Group B, but this difference 236 
was not statistically significant. At Visit 2, comfort scores significantly decreased in Group A and increased in 237 
Group B (Table 2) (Figure 7). 238 
 239 
Skin conductance 240 
For Visit 1, a mixed, between-within subjects ANOVA was conducted to assess the impact of two different 241 
interventions (effect of drops) on subjects’ maximal SC response across three time periods (lens insertion, 242 
adaptation to lenses, and lens removal). There was no significant interaction between drop and time (Wilks 243 
Lambda, p=0.97). There was no significant main effect for time (p=0.97). The main effect comparing the 244 
groups, depending on the type of drop instilled, was not significant (p=0.64). A one-way repeated measures 245 
ANOVA was conducted to compare maximal SC responses over time, but no significant effect of time was 246 
found (Group A, p=0.78; Group B, p=0.98). 247 
 248 
For Visit 2, a mixed, between-within subjects ANOVA found no significant interaction between drop and time 249 
(Wilks Lambda, p=0.82), nor was there a significant main effect for time (p=0.84). The main effect comparing 250 
the groups, depending on the type of drop instilled, was not significant (p=0.18). 251 
 252 
Discussion 253 
The findings from this study indicate that TA is beneficial in reducing both objective anxiety measurements 254 
during adaptation to GP CLs and self-reported anxiety prior to second-time lens insertion, while producing 255 
no clinically significant physiological changes. However, this benefit for subsequent lens wear may produce a 256 
falsely raised expectation for future CL wearing comfort. 257 
 258 
The use of TA during GP CL fitting has been demonstrated to be a clinically safe practice with potential 259 
patient benefits including improved first-time GP CL wear comfort, reduced anxiety during adaptation and 260 
reduced anxiety prior to second-time GP CL wear. The use of TA itself did not adversely increase ocular 261 
surface hyperaemia or corneal staining response during lens fitting. At the second visit, the ocular redness 262 
response to GP CLs was reduced, irrespective of previous drop experience (TA or placebo). Comfort at initial 263 
fitting was marginally improved with TA, although it was worse at the dispensing visit. Patients who received 264 
TA during fitting had significantly reduced anxiety (VAS) prior to lens collection, suggesting that this practice 265 
may minimise CL drop-out rates. The disadvantages of TA use may be the reduced comfort during second-266 
time GP CL wear when no TA is administered. 267 
 268 
These findings concur with a previous study which reported reduced drop-out rates in first-time wearers 269 
fitted with use of TA at fitting and dispensing visits4. A similar study fitted apprehensive patients using TA 270 
and reported superior comfort, less alteration to blink rate and less tearing compared with a control group. 271 
Furthermore, 50% of subjects felt confident about wearing GP CLs following fitting with TA compared with 272 
20% of control subjects4. The study also reported the use of TA to significantly reduce time for GP CL 273 
stabilisation on the eye. (GP CL stabilisation time, blink rate or lacrimation were not measured during this 274 
investigation). Effect of TA on GP CL stabilisation time might be of interest as the time needed to fit GP CLs is 275 
perceived to be greater than that for soft CL fitting. The use of TA to shorten fitting appointments might be a 276 
further indication for TA use in GP CL fitting. 277 
 278 
Physiological response 279 
The collective mean (n=47) baseline bulbar conjunctiva hyperaemia CCLRU grade was 1.81±0.27 units at Visit 280 
1 and 1.70±0.21 units at Visit 2. Murphy et al (2007) indicated that bulbar conjunctiva hyperaemia grading 281 
with the CCLRU normally ranges from 1.3-2.6 units, and a grade of more than 2.6 should be considered 282 
abnormal. Most eye care practitioners (ECPs) would accept that slight increases in ocular surface hyperaemia 283 
occur when CLs are first applied. Due to inter-subject variability, measurement of change in bulbar 284 
conjunctiva hyperaemia is more meaningful than absolute values, with a change of 0.4 units considered as 285 
clinically significant24. The results here indicate that the mean increase in hyperaemia grades during the GP 286 
CL trial were small (less than one quarter of a CCLRU grade), but statistically significant. Importantly, the 287 
study demonstrated that use of TA did not promote a clinically significant increase in hyperaemia in this 288 
cohort. 289 
 290 
Hyperaemia increase at Visit 2 was statistically more significant in Group A than Group B. A possible 291 
explanation for these findings might be that the Group B hyperaemic reaction was conditioned by an 292 
improvement in comfort experience at the second exposure to GP lenses. Meanwhile, subjects in Group A, 293 
who received TA at Visit 1 experienced a reduced level of ocular comfort at Visit 2, and therefore responded 294 
as if they were naïve to GP CLs. An alternative explanation might be that, while baseline hyperaemia grades 295 
were greater in Group B than Group A (p=0.06), the mean increase in redness was small and similar (p<0.05) 296 
for both groups. 297 
 298 
It has been reported that a mean CCLRU corneal staining grade of 0.1 (max 0.5) should be anticipated for 299 
non-CL wearers25. However, the cohort reported here included both non-CL wearers and soft CL (SCL) 300 
wearers. SCL wear alters cell exfoliation and proliferation in the corneal and limbal epithelia resulting in 301 
increased staining26,27. This study found a mean baseline corneal staining grade of 0.23±0.39 units, which was 302 
marginally higher than the Dundas et al.25 study for non-CL wearers, and marginally less than the mean 303 
Grade 0.5 reported in a study of asymptomatic hydrogel CL wearers28. Our study found <0.1 unit difference 304 
in mean corneal staining grade (post-GP CL wear) between the placebo and TA group. Although mean 305 
change in corneal staining grade was larger in the TA group, this difference was not statistically significant. 306 
Similar studies have also reported no significant increase in corneal staining with TA use compared with a 307 
control drop29,30. 308 
 309 
This result is perhaps surprising given that most optometrists will anecdotally report a reluctance to use TA 310 
due to its ‘toxic effect’. Yet, UK practitioners routinely instil TA prior to clinical techniques such as Goldmann 311 
applanation tonometry24. Clinicians are aware of the potential risks associated with TA use, but consider that 312 
the benefits of producing corneal anaesthesia outweigh them. Indeed, TA is known to be mildly toxic to the 313 
corneal epithelium20. One study investigating corneal staining reported 17.6% of eyes stained with 314 
fluorescein at baseline measurement, but that following TA instillation (oxybuprocaine and tetracaine), 60% 315 
of eyes stained with fluorescein31. However, it is likely that the preservative (0.01%, benzalkonium chloride) 316 
accompanying the TA in that study was responsible for the staining increase. Research has reported that 317 
sequential instillation of TA was not responsible for increased epithelial permeability, but the addition of 318 
preservatives significantly increases corneal permeability31. Preservative-free TA minims (0.5%, 319 
proxymetacaine) were used in this study to reduce the risk of ocular surface response associated with 320 
preservative. Repeated use of TA can delay wound healing or cause keratitis31, but only one drop of TA was 321 
used in this study. 322 
 323 
At Visit 2, the results indicated that corneal staining was increased in all subjects following GP CL insertion, 324 
but the mean grade increase was not clinically significant for either Group A or B34. 325 
 326 
Physiological response 327 
Measured trait anxiety at the start of each visit (although not expected to change between visits) confirmed 328 
an even distribution of tendencies toward anxiety in both groups, i.e. there was no skew in either group 329 
towards very sensitive individuals. State anxiety refers to the transient or current level of anxiety 330 
experienced by the subject. Variations in volunteer personality types and extraneous factors, which might 331 
have influenced state anxiety levels, may produce the wide variation observed in results prior to the Visit 1 332 
CL trial. Importantly, both measures of anxiety (state anxiety and VAS) were not significantly different 333 
between Groups A and B at Visit 1. Both groups were naïve to GP CLs and masked as to whether they would 334 
receive TA or placebo drops. 335 
 336 
At Visit 2, subjects who had previously received TA at Visit 1, showed less anxiety when measured with the 337 
VAS, but no significant change in state anxiety scoring. It may be that the state score was affected by 338 
extraneous stress factors and this masked the reduction in anxiety relating specifically to GP CL insertion. 339 
Conversely, the placebo group state anxiety scores showed a significant increase at Visit 2 implying that their 340 
negative experience at Visit 1 caused them to feel more anxious in anticipation of GP CL insertion for the 341 
second time. However, this was not the case for their anxiety VAS responses, which showed no significant 342 
change from Visit 1. This is perhaps because subjects were no longer naïve to GP CLs and knew what to 343 
expect (i.e. no fear of the unknown as at Visit 1). Social anxiety research indicates that within a formal 344 
encounter people generally want to make a good impression and want to avoid appearing foolish34. 345 
Therefore, an alternative explanation may be that subjects were too embarrassed to admit to feeling 346 
anxious at the prospect of second-time GP CL discomfort experience, a condition more easily expressed on a 347 
simple VAS. 348 
 349 
During CL fitting, subjects who had received TA appeared less ‘aroused’ during the adaptation period than 350 
the placebo group. This seems a logical finding as Group A subjects were anaesthetised and therefore 351 
experienced better comfort, and consequently reduced stress levels. Apart from reduced corneal sensitivity, 352 
other factors which may affect stress levels during adaptation to lenses might have included change in vision 353 
due to the power of the trial lens (-3.00 Dioptres), acceptability of the CL fit, and individual lid architecture or 354 
tightness. However, the effects of these factors should have been equal for both groups. 355 
 356 
At Visit 2, SC appeared somewhat heightened in the anaesthetic group because they now experienced the 357 
full sensation of the GP CL, whereas Group B had lower SC response since they experienced an improved 358 
level of comfort at second exposure to GP CLs. However, statistically there was no difference in the results 359 
for the two groups. 360 
 361 
Electrodermal activity is the most widely accepted measure of arousal or anxiety, and SC is the best objective 362 
measurement of electrodermal activity36. Previous research has investigated SC during soft CL fitting and 363 
reported characteristic anxiety fluctuations during the consultation. Specifically, heightened stress response 364 
during CL insertion and CL removal was reported37,38. Visual inspection of each trace produced by subjects in 365 
this study found heightened SC response during CL insertion and removal. However, this research was 366 
specifically interested in alterations to the SC response due to the use of TA during GP CL fitting. The trends 367 
shown in the results indicate that there may be a reduction in anxiety with TA, however the results were not 368 
statistically significant. Trends may become significant with increased sample size. 369 
 370 
At Visit 2, VAS comfort levels were improved in the group (A) that received TA prior to initial CL fitting, but 371 
this was not significantly better than the placebo group (B) (p=0.12). This lack of statistical significance may 372 
be because there was a wide variation in comfort scores and the sample size. If the cohort had been larger, it 373 
is likely that this trend would have shown statistical significance. It may be that the superior palpebral 374 
conjunctiva is less well anaesthetised due to application of the drop to the inferior palpebral conjunctiva. 375 
This is supported by the idea that comfort during GP CL wear may be more directly linked to sensitivity of the 376 
superior tarsal plate and the position of the CL margin in relation to the superior lid3. 377 
 378 
It is possible that there could be a negative outcome from the use of TA, arising from the decreased comfort 379 
experienced by first visit TA subjects, at the second non-TA visit. In this situation, the subject experiences 380 
more discomfort, which may promote cessation of GP CL wear. However, the reduced anxiety levels at the 381 
second visit for the first visit TA subjects is a strong indication that subjects, although experiencing higher 382 
levels of discomfort, are calmer about the whole lens fit process. This tends to support the benefit of TA use 383 
in GP CL fitting. A prospective study with GP CL fitting in healthy subjects under normal clinical conditions 384 
would be a useful extension of this study, by allowing the investigation of whether lens fit complexity can 385 
have an impact on patient anxiety. 386 
 387 
In summary, use of TA in GP CL fitting has been demonstrated to be clinically safe practice that may enhance 388 
first GP CL lens experience, especially in anxious patients, reduce anxiety during GP CL adaptation, and 389 
reduce anxiety prior to subsequent GP CL wear. 390 
 391 
392 
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471 
Tables 472 
Visit 1 
Pre-GP 
fitting 
Post-GP 
fitting 
Difference in 
grading Pre- and 
Post-GP wear 
Difference 
between Groups 
A and B 
Mean±sd Mean±sd 
Mean±sd 
(Paired t-test) 
Mean±sd 
(Ind t-test) 
Conjunctival 
hyperaemia 
Group A 1.84±0.28 2.08±0.43 0.25±0.25 (p<0.05) 0.10±0.64 
(p=0.15) Group B 1.78±0.26 1.93±0.34 0.15±0.16 (p<0.05) 
Limbal 
hyperaemia 
Group A 1.59±0.42 1.91±0.50 0.26±0.56 (p<0.05) 0.01±0.14 
(p=0.93) Group B 1.52±0.28 1.78±0.40 0.27±0.26 (p<0.05) 
Corneal 
staining 
Group A 0.19±0.27 0.63±0.66 0.44±0.56 (p<0.05) 0.17±0.16 
(p=0.30) Group B 0.28±0.49 0.55±0.66 0.27±0.54 (p<0.05) 
Visit 2 
Pre-GP 
fitting 
Post-GP 
fitting 
Difference in 
grading Pre- and 
Post-GP wear 
Difference 
between Groups 
A and B 
Mean±sd Mean±sd 
Mean±sd 
(Paired t-test) 
Mean±sd 
(Ind t-test) 
Conjunctival 
hyperaemia 
Group A 1.67±0.15 1.78±0.21 0.03±0.36 (p<0.05) 0.01±0.08 
(p=0.86) Group B 1.73±0.27 1.78±0.31 0.04±0.12 (p=0.11) 
Limbal 
hyperaemia 
Group A 1.51±0.34 1.69±0.26 0.10±0.42 (p<0.05) 0.03±0.10 
(p=0.73) Group B 1.51±0.29 1.56±0.31 0.07±0.16 (p=0.15) 
Corneal 
staining 
Group A 0.31±0.32 0.68±0.49 0.37±0.37 (p<0.05) 0.25±0.09 
(p<0.05) Group B 0.32±0.41 0.44±0.44 0.12±0.17 (p<0.05) 
 473 
Table 1: CCLRU grading measurements for Group A (TA) and Group B (placebo) at each visit. 474 
 475 
476 
 477 
Anxiety VAS 
Group A 
(TA drop) 
Group B 
(placebo) 
Mann-Whitney 
Test 
Visit 1 score 
(%) 
Median 
Range 
13.57 
0.00-84.29 
9.29 
0.00-74.29 
p=0.33 
Visit 2 score 
(%) 
Median 
Range 
10.71 
0.00-35.71 
17.14 
0.00-55.71 
p=0.31 
Wilcoxon Rank test p<0.05 p=0.94  
Comfort VAS 
Group A 
(TA drop) 
Group B 
(placebo) 
Mann-Whitney 
Test 
Visit 1 score 
(%) 
Median Range 
28.57 
2.86-100.00 
26.79 
2.86-97.86 
p=0.25 
Visit 2 score 
(%) 
Median 
Range 
22.86 
0.00-100.00 
58.57 
0.00-98.57 
p=0.12 
Wilcoxon Rank test p<0.05 p<0.05  
 478 
Table 2: VAS anxiety and comfort results for Groups A and B at each visit. 479 
 480 
481 
Figures 482 
Figure Legends 483 
Table 1: CCLRU grading measurements for Group A (TA) and Group B (placebo) at each visit. 484 
Table 2: VAS anxiety and comfort results for Groups A and B at each visit. 485 
 486 
Figure 1: Example of raw skin conductance trace, showing marker tags. 487 
Figure 2: Error plots showing mean±sd in CCLRU grading scores pre- and post-GP fitting at Visit 1. A: 488 
Conjunctival hyperaemia, B: Limbal hyperaemia and C: Corneal staining. 489 
Figure 3: Error plots showing mean±sd CCLRU grading scores pre- and post-GP fitting at Visit 2; A: 490 
Conjunctival hyperaemia, B: Limbal hyperaemia and C: Corneal staining. 491 
Figure 4: Mean change in CCLRU grading scores during Visits 1 and 2 for Groups A and B. 492 
Figure 5: Box plot of median and range of state anxiety scores for Groups A and B at Visits 1 and 2. 493 
Figure 6: Box plot of median and range of VAS anxiety scores for Groups A and B prior to GP insertion at 494 
Visits 1 and 2. 495 
Figure 7: Box plot of median and range of VAS comfort scores for Groups A and B at Visits 1 and 2. 496 
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 511 
 512 
Figure 1: Example of raw skin conductance trace, showing marker tags. Tag 1: Examiner says: “I’m going to 513 
out a drop into yours eyes now”; Tag 2: Examiner says: “I’m now going to insert the lenses to your eyes”; Tag 514 
3: Completion of lens insertion; Tag 4: Examiner says: “I’m now going to remove the lenses from your eyes”; 515 
Tag 5: Completion of lens removal. 516 
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Figure 2: Error plots showing mean±sd CCLRU grading scores pre- and post-GP lens fitting at Visit 1. A: 540 
Conjunctival hyperaemia, B: Limbal hyperaemia and C: Corneal staining. 541 
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 566 
Figure 3: Error plots showing mean±sd CCLRU grading scores pre- and post-GP lens fitting at Visit 2; A: 567 
Conjunctival hyperaemia, B: Limbal hyperaemia and C: Corneal staining. 568 
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 571 
Figure 4: Mean change in CCLRU grading scores during Visits 1 and 2 for Groups A and B. 572 
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 578 
Figure 5: Box plot of median and range of state anxiety scores (from the shortened 6-item version of the 579 
Spielberger State-Trait Inventory (STAI) questionnaire) for Groups A and B at Visits 1 and 2 (whiskers 580 
represent the 10th and 90th percentiles). 581 
582 
 583 
 584 
 585 
 586 
 587 
 588 
 589 
 590 
 591 
 592 
 593 
 594 
 595 
 596 
Figure 6: Box plot of median and range of VAS anxiety scores for Groups A and B prior to GP lens insertion at 597 
Visits 1 and 2. 598 
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 613 
Figure 7: Box plot of median and range of VAS comfort scores for Groups A and B at Visits 1 and 2. 614 
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